Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?

Nuvation Bio's Chief People Officer Stacy Markel sold 125,000 shares worth $753,000 on June 23, 2026, reducing her direct holdings by 79.32%. However, the sale was executed under a pre-established trading plan adopted in December 2025, and Markel retains significant exposure through 629,810 outstanding options. Despite the stock's 190% surge over the past year and recent 40% pullback from December highs, the article suggests investors should focus more on the company's ability to convert regulatory wins into commercial growth, particularly with taletrectinib's global launch.